Avalanche Biotechnologies Closes Transaction With Annapurna Therapeutics
Avalanche Biotechnologies, Inc. (AAVL) today announced the closing of the previously announced transaction with Annapurna Therapeutics. “The new management team is focused on applying our extensive clinical development expertise to advance the company’s gene therapy programs into the clinic. We intend on dosing our first patients for A1AT deficiency by the end of this year…